C9098
Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Terminated September 30, 2022.
Notice
-
HCPCS C9098 terminated on September 30, 2022.
Short Description
-
Ciltacabtagene car pos t
HCPCS Coverage Code
-
C = Carrier judgment
HCPCS Action Code
-
N = No maintenance for this code
HCPCS Action Effective Date
-
October 01, 2022
HCPCS Code Added Date
-
July 01, 2022
HCPCS Termination Date
-
September 30, 2022
HCPCS Pricing Indicator Code
-
53 = Statute
HCPCS Multiple Pricing Indicator Code
-
A = Not applicable as HCPCS priced under one methodology
HCPCS Type Of Service Code
-
1 = Medical care
HCPCS Anesthesia Base Unit Quantity
-
0